References: Principles of recovery and relapse prevention in psychoses including schizophrenia

  • Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014;4(5):198–219. https://www.ncbi.nlm.nih.gov/pubmed/25360245
  • Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020;8:CD008016. https://www.ncbi.nlm.nih.gov/pubmed/32840872
  • Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence. J Clin Psychiatry 2016;77(suppl 3):1–24. https://www.ncbi.nlm.nih.gov/pubmed/27732772
  • De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015;29(8):637–58. https://www.ncbi.nlm.nih.gov/pubmed/26293744
  • Early Psychosis Guidelines Writing Group, EPPIC National Support Program. Australian clinical guidelines for early psychosis. 2nd Melbourne: Orygen, the National Centre of Excellence in Youth Mental Health; 2016. https://www.orygen.org.au/Training/Resources/Psychosis/Clinical-practice-points/Australian-Clinical-Guidelines-for-Early-Psychosis
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014;40(1):192–213. https://www.ncbi.nlm.nih.gov/pubmed/23256986
  • Taipale H, Mehtala J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull 2018;44(6):1381–7. https://www.ncbi.nlm.nih.gov/pubmed/29272458
  • Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 2017;74(7):686–93. https://www.ncbi.nlm.nih.gov/pubmed/28593216
  • Tiihonen J, Taipale H, Mehtala J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019. https://www.ncbi.nlm.nih.gov/pubmed/30785608
  • Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018;175(8):765–73. https://www.ncbi.nlm.nih.gov/pubmed/29621900